Approaches to Diagnosis and Treatment of Acute Male Urethritis: Results of Multicenter Observational Study

Clinical Microbiology and Antimicrobial Chemotherapy. 2011; 13(1):19-39

​ Kozlov S.N., Korolyov S.V., Andreeva I.V., Belikov A.N., Grinev A.V., Evstafiev V.V., Kirpitchyova N.N., Serdyutskaya M.V., Stetsiouk O.U., Fokin A.A.
urethritis pharmacoepidemiology diagnosis antimicrobial therapy
Section
Diseases and Pathogens
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2011; 13(1):19-39

Objective.

Objectives. To determine the diagnostic and treatment patterns for acute male urethritis (AMU) in Russia.

Materials and Methods.

Retrospective cross-sectional study was conducted during 2009 in 4 cities of Russia: Kaluga, Pskov, Smolensk and Tula. Data on diagnostic and treatment approaches for AMU subjects ≥16 years old were collected and analyzed using specially designed case report forms.

Results.

556 cases of AMU were analyzed during study period. The average age of patients was 29 years (16–68 years). The following diagnostic methods were used in 96.4% of cases (C. trachomatis: PCR (138⁄24.8%), ELISA (156⁄28.1%); N. gonorrhoeae and T. vaginalis, respectively: urethral smear microscopy (445⁄80.0% and 320⁄57.6%), PCR (109⁄19.6% and 130⁄23.4%); U. urealyticum and M. hominis, respectively: bacteriology (140⁄25.2% and 135⁄24.3%), PCR (135⁄24.3% and 133⁄23.9%); M. genitalium: PCR (135⁄24.3%). The most common diagnosis in center #1 was gonococcal urethritis (GU) (61.7%), in centers ##2, 3, 5 – non-gonococcal urethritis (NGU) (68.0, 54.7, 66.3%), in center #4 – unspecified urethritis (45.1%) and NGU (36.3%). Treatment patterns included antimicrobials (ABx) solely in 66.3, and ABx + non-ABx – in 32.2% of cases.

Conclusions.

According to the results, use of standard methods for AMU diagnosis was rather rare and ABx treatment in some cases was not in compliance with modern practical guidelines for STD and AMU.

  • 1. Workowski K.A., Berman S.; Centers for Disease Control and Prevention (CDC). Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR Recomm Rep. 2010; 59(RR-12): 1-10.
  • 2. Riemersma W., Van Der Schee C., Van Der Meijden W., et al. Microbial population diversity in the urethras of healthy males and males suffering from nonchlamydial, nongonococcal urethritis. J Clin Microbiol 2003; 41:1977- 86.
  • 3. Global Prevalence and Incidence of Selected Curable Sexually Transmitted Infections Overview and Estimates, World Health Organization, 2001. Available from: http://www.who.int/docstore/hiv/GRSTI.
  • 4. Beagley K.W., Timms P. Chlamydia trachomatis infection: incidence, health costs and prospects for vaccine development. J Reprod Immunol 2000; 48:47-68.
  • 5. Dupin N., Bijaoui G., Schwarzinger M., et al. Detection and quantification of Mycoplasma genitalium in male patients with urethritis. Clin Infect Dis 2003; 37:602-5.
  • 6. Horner P., Thomas B., Gilroy C.B., et al. Role of Mycoplasma genitalium and Ureaplasma urealyticum in acute and chronic nongonococcal urethritis. Clin Infect Dis 2001; 32:995-1003.
  • 7. Taylor-Robinson D., Gilroy C.B., Thomas B.J., et al. Mycoplasma genitalium in chronic non-gonococcal urethritis. Int J STD AIDS 2004; 15:21-5.
  • 8. Naber K.G., Schaeffer A.J., Heyns C., et al., Editors. Urogenital infections. European Association of Urology, 2010.
  • 9. Madeb R., Nativ O., Benilevi D., et al. Need for diagnostic screening of herpes simplex virus in patients with nongonococcal urethritis. Clin Infect Dis 2000; 30: 982-3.
  • 10. Bradshaw C.S., Tabrizi S.N., Read T.R., et al. Etiologies of nongonococcal urethritis: bacteria, viruses, and the association with orogenital exposure. J Infect Dis 2006; 193:336-45.
  • 11. Shahmanesh M., Moi H., Lassau F., Janier M.; IUSTI/ WHO. 2009 European guideline on the management of male non-gonococcal urethritis. Int J STD AIDS 2009; 20:458-64.
  • 12. Национальный стандарт «Гонококковая инфекция. Неосложненная форма» (проект). Врач. 2008; Специальный выпуск: 27-46.
  • 13. Национальный стандарт «Урогенитальный трихомониаз. Неосложненная форма» (проект). Врач. 2008; Специальный выпуск: 48-64.
  • 14. Национальный стандарт «Хламидийная инфекция. Неосложненная форма» (проект). Врач. 2008; Специальный выпуск: 5-26.
  • 15. Lanjouw E., Ossewaarde J.M., Stary A., et al. 2010 European guideline for the management of Chlamydia trachomatis infections. Int J STD AIDS 2010; 21:729-37.
  • 16. Watson E.J., Templeton A., Russell I., et al. The accuracy and efficacy of screening tests for Chlamydia trachomatis: a systematic review. J Med Microbiol 2002; 51:1021-31.
  • 17. Страчунский Л.С., Сехин С.В., Борисенко К.К. и др. Чувствительность гонококков к антибиотикам и выбор антибактериальных препаратов при гонококковой инфекции. ИППП. 1999; (2):26-9.
  • 18. Kubanova A., Frigo N., Kubanov A., et al. National surveillance of antimicrobial susceptibility in Neisseria gonorrhoeae in 2005–2006 and recommendations of first-line antimicrobial drugs for gonorrhoea treatment in Russia. Sex Transm Infect 2008; 84:285-9.
  • 19. Update to CDC’s sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 2007; 56:332-6.
  • 20. Kubanova A., Frigo N., Kubanov A., et al. The Russian gonococcal antimicrobial susceptibility programme (RU-GASP)--national resistance prevalence in 2007 and 2008, and trends during 2005–2008. Euro Surveill 2010; 15:pii 19533.
  • 21. Lyss S.B., Kamb M.L., Peterman T.A., et al. Chlamydia trachomatis among patients infected with and treated for Neisseria gonorrhoeae in sexually transmitted disease clinics in the United States. Ann Intern Med 2003; 139:178-85.
  • 22. Кубанова А.А., Рахматуллина М.Р. Урогенитальные инфекционные заболевания, вызванные генитальными микоплазмами. Клинические рекомендации. Consilium Medicum. 2009; (6):32-6.
  • 23. Инструкция к препарату Зетамакс ретард. http://www.vidal.ru/poisk_preparatov/zetamax-retard.htm.
  • 24. Cornely O.A., Böhme A., Buchheidt D., et al; Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors – guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82 Suppl 2:S186-200.
  • 25. Ship J.A., Vissink A., Challacombe S.J. Use of prophylactic antifungals in the immunocompromised host. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103:S6.e1-14.
  • 26. Cruciani M., Mengoli C., Malena M., et al. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl 2006; 12:850- 85.
  • 27. Patterson R., Grammer L.C., Greenberger P.A. Allergic Diseases: Diagnosis and Management. Lippincott Williams & Wilkins; 5th edition, 1997, 634 p.
  • 28. Babe K.S., Serafin W.E. Histamine bradykinin, and their antagonists. In: Hardman J.G., Limbird L.E., Molinoff P.В., Ruddon R.W., eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996:581-600.
  • 29. Fung M, Scott KC, Kent CK, et al. Chlamydial and gonococcal reinfection among men: a systematic review of data to evaluate the need for retesting. Sex Transm Infect 2007; 83:304-9.
  • 30. Kissinger P.J., Reilly K., Taylor S.N., et al. Early repeat Chlamydia trachomatis and Neisseria gonorrhoeae infections among heterosexual men. Sex Transm Dis 2009; 36:498-500.
  • 31. Workowski K.A., Berman S.M., Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55 (RR-11):1-94.
  • 32. Johnson R.E., Newhall W.J., Papp J.R., et al. Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections – 2002. MMWR Recomm Rep 2002; 51:1-38.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared